Rocaglamide-A Potentiates Osteoblast Differentiation by Inhibiting NF-κB Signaling |
Li, Aiguo
(Department of Orthopedic Surgery, The First Affiliated Hospital of Xinxiang Medical University)
Yang, Libin (Department of Orthopedic Surgery, The First Affiliated Hospital of Xinxiang Medical University) Geng, Xiaolin (Department of Orthopedic Surgery, The First Affiliated Hospital of Xinxiang Medical University) Peng, Xingmei (Department of Oncology, The Third Affiliated Hospital of Xinxiang Medical University) Lu, Tan (Department of Orthopedic Surgery, The First Affiliated Hospital of Xinxiang Medical University) Deng, Yanjun (Department of Orthopedic Surgery, The First Affiliated Hospital of Xinxiang Medical University) Dong, Yuzheng (Department of Orthopedic Surgery, The First Affiliated Hospital of Xinxiang Medical University) |
1 | Azuma, Y., Kaji, K., Katogi, R., Takeshita, S. and Kudo, A. (2000) Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. J. Biol. Chem. 275, 4858-4864. DOI |
2 | Baumann, B., Bohnenstengel, F., Siegmund, D., Wajant, H., Weber, C., Herr, I., Debatin, K.M., Proksch, P., and Wirth, T. (2002). Rocaglamide derivatives are potent inhibitors of NF-kappa B activation in T-cells. J. Biol. Chem. 277, 44791-44800. DOI |
3 | Bohnenstengel, F.I., Steube, K.G., Meyer, C., Nugroho, B.W., Hung, P.D., Kiet, L.C., and Proksch, P. (1999). Structure activity relationships of antiproliferative rocaglamide derivatives from Aglaia species (Meliaceae). Z. Naturforsch. C 54, 55-60. |
4 | Canalis, E. (1987) Effects of tumor necrosis factor on bone formation in vitro. Endocrinology 121, 1596-1604. DOI |
5 | Chang, J., Wang, Z., Tang, E., Fan, Z., McCauley, L., Franceschi, R., Guan, K., Krebsbach, P.H., and Wang, C.Y. (2009). Inhibition of osteoblastic bone formation by nuclear factor-kappaB. Nat. Med. 15, 682-689. DOI |
6 | Chang, J., Liu, F., Lee, M., Wu, B., Ting, K., Zara, J.N., Soo, C., Al Hezaimi, K., Zou, W., Chen, X., et al. (2013). NF-kappaB inhibits osteogenic differentiation of mesenchymal stem cells by promoting beta-catenin degradation. Proc. Natl. Acad. Sci. USA 110, 9469-9474. DOI |
7 | Collett, G.P. and Campbell, F.C. (2006) Overexpression of p65/RelA potentiates curcumin-induced apoptosis in HCT116 human colon cancer cells. Carcinogenesis 27, 1285-1291. DOI |
8 | Dreyer, M., Nugroho, B.W., Bohnenstengel, F.I., Ebel, R., Wray, V., Witte, L., Bringmann, G., Muhlbacher, J., Herold, M., Hung, P.D., et al. (2001). New insecticidal rocaglamide derivatives and related compounds from Aglaia oligophylla. J. Nat. Prod. 64, 415-420. DOI |
9 | Goldring, S.R. and Gravallese, E.M. (2000) Pathogenesis of bone erosions in rheumatoid arthritis. Curr. Opin. Rheumatol 12, 195-199. DOI |
10 | Huang, W., Yang, S., Shao, J. and Li, Y.P. (2007) Signaling and transcriptional regulation in osteoblast commitment and differentiation. Front. Biosci. 12, 3068-3092. DOI |
11 | Lee, S.K., Cui, B., Mehta, R.R., Kinghorn, A.D., and Pezzuto, J.M. (1998). Cytostatic mechanism and antitumor potential of novel 1H-cyclopenta[b]benzofuran lignans isolated from Aglaia elliptica. Chem. Biol. Interact. 115, 215-228. DOI |
12 | Kaneko, H., Arakawa, T., Mano, H., Kaneda, T., Ogasawara, A., Nakagawa, M., Toyama, Y., Yabe, Y., Kumegawa, M. and Hakeda, Y. (2000). Direct stimulation of osteoclastic bone resorption by bone morphogenetic protein (BMP)-2 and expression of BMP receptors in mature osteoclasts. Bone 27, 479-486. DOI |
13 | Karsenty, G., Kronenberg, H.M. and Settembre, C. (2009) Genetic control of bone formation. Annu. Rev. Cell Dev. Biol. 25, 629-648. DOI |
14 | Kim, S., Salim, A.A., Swanson, S.M., and Kinghorn, A.D. (2006). Potential of cyclopenta[b]benzofurans from Aglaia species in cancer chemotherapy. Anticancer Agents Med. Chem. 6, 319-345. DOI |
15 | Lee, H.L., Yi, T., Woo, K.M., Ryoo, H.M., Kim, G.S., and Baek, J.H. (2010). Msx2 mediates the inhibitory action of TNF-alpha on osteoblast differentiation. Exp. Mol. Med. 42, 437-445. DOI |
16 | Li, Y.C., Ross, J., Scheppler, J.A., and Franza, B.R., Jr. (1991). An in vitro transcription analysis of early responses of the human immunodeficiency virus type 1 long terminal repeat to different transcriptional activators. Mol. Cell Biol. 11, 1883-1893. DOI |
17 | Li, Y., Li, A., Strait, K., Zhang, H., Nanes, M.S., and Weitzmann, M.N. (2007). Endogenous TNFalpha lowers maximum peak bone mass and inhibits osteoblastic Smad activation through NF-kappaB. J. Bone Miner Res. 22, 646-655. DOI |
18 | McInnes, I.B., and Schett, G. (2007). Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol. 7, 429-442. DOI |
19 | Mukai, T., Otsuka, F., Otani, H., Yamashita, M., Takasugi, K., Inagaki, K., Yamamura, M. and Makino, H. (2007). TNF-alpha inhibits BMP-induced osteoblast differentiation through activating SAPK/JNK signaling. Biochem. Biophys. Res. Commun. 356, 1004-1010. DOI |
20 | Mosmann, T. (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55-63. DOI |
21 | Nanjundaiah, S.M., Astry, B. and Moudgil, K.D. (2013) Mediators of inflammation-induced bone damage in arthritis and their control by herbal products. Evid. Based Complement Alternat. Med. 2013, 518094. |
22 | Proksch, P., Giaisi, M., Treiber, M.K., Palfi, K., Merling, A., Spring, H., Krammer, P.H. and Li-Weber, M. (2005). Rocaglamide derivatives are immunosuppressive phytochemicals that target NF-AT activity in T cells. J. Immunol. 174, 7075-7084. DOI |
23 | Redlich, K., Hayer, S., Ricci, R., David, J.P., Tohidast-Akrad, M., Kollias, G., Steiner, G., Smolen, J.S., Wagner, E.F. and Schett, G. (2002). Osteoclasts are essential for TNF-alpha-mediated joint destruction. J. Clin. Invest. 110, 1419-1427. DOI |
24 | Smucker, J.D., Rhee, J.M., Singh, K., Yoon, S.T., and Heller, J.G. (2006). Increased swelling complications associated with off-label usage of rhBMP-2 in the anterior cervical spine. Spine 31, 2813-2819. DOI |
25 | Stanford, C.M., Jacobson, P.A., Eanes, E.D., Lembke, L.A. and Midura, R.J. (1995) Rapidly forming apatitic mineral in an osteoblastic cell line (UMR 106-01 BSP). J. Biol. Chem. 270, 9420-9428. DOI |
26 | Yamazaki, M., Fukushima, H., Shin, M., Katagiri, T., Doi, T., Takahashi, T. and Jimi, E. (2009) Tumor necrosis factor alpha represses bone morphogenetic protein (BMP) signaling by interfering with the DNA binding of Smads through the activation of NF-kappaB. J. Biol. Chem. 284, 35987-35995. DOI |
27 | Steer, J.H., Kroeger, K.M., Abraham, L.J. and Joyce, D.A. (2000). Glucocorticoids suppress tumor necrosis factor-alpha expression by human monocytic THP-1 cells by suppressing transactivation through adjacent NF-kappa B and c-Jun-activating transcription factor-2 binding sites in the promoter. J. Biol. Chem. 275, 18432-18440. DOI |
28 | Walsh, N.C., Reinwald, S., Manning, C.A., Condon, K.W., Iwata, K., Burr, D.B. and Gravallese, E.M. (2009). Osteoblast function is compromised at sites of focal bone erosion in inflammatory arthritis. J. Bone Miner Res. 24, 1572-1585. DOI |
29 | Wong, D.A., Kumar, A., Jatana, S., Ghiselli, G., and Wong, K. (2008). Neurologic impairment from ectopic bone in the lumbar canal: a potential complication of off-label PLIF/TLIF use of bone morphogenetic protein-2 (BMP-2). Spine J. 8, 1011-1018. DOI |
30 | Zaidi, M. (2007) Skeletal remodeling in health and disease. Nat. Med. 13, 791-801. DOI |
31 | Zhu, J.Y., Giaisi, M., Kohler, R., Muller, W.W., Muhleisen, A., Proksch, P., Krammer, P.H. and Li-Weber, M. (2009). Rocaglamide sensitizes leukemic T cells to activation-induced cell death by differential regulation of CD95L and c-FLIP expression. Cell Death Differ. 16, 1289-1299. DOI |
32 | Zara, J.N., Siu, R.K., Zhang, X., Shen, J., Ngo, R., Lee, M., Li, W., Chiang, M., Chung, J., Kwak, J., et al. (2011). High doses of bone morphogenetic protein 2 induce structurally abnormal bone and inflammation in vivo. Tissue Eng. Part A 17, 1389-1399. DOI |